Ascendis Pharma A/S (NASDAQ:ASND) Receives $191.77 Consensus Price Target from Analysts

Ascendis Pharma A/S (NASDAQ:ASND) has received a consensus rating of “Moderate Buy” from the thirteen analysts that are currently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the company. The average 1 year price target among analysts that have covered the stock in the last year is $191.77.

Several brokerages recently commented on ASND. Wells Fargo & Company increased their target price on shares of Ascendis Pharma A/S from $264.00 to $289.00 and gave the stock an “overweight” rating in a report on Tuesday, September 17th. Citigroup increased their price objective on shares of Ascendis Pharma A/S from $178.00 to $207.00 and gave the stock a “buy” rating in a research note on Tuesday, September 17th. Stifel Nicolaus raised their price objective on Ascendis Pharma A/S from $200.00 to $207.00 and gave the company a “buy” rating in a report on Friday, November 15th. Cantor Fitzgerald reiterated an “overweight” rating and set a $170.00 target price on shares of Ascendis Pharma A/S in a report on Friday, November 15th. Finally, Oppenheimer decreased their price target on Ascendis Pharma A/S from $190.00 to $180.00 and set an “outperform” rating for the company in a research note on Friday, November 15th.

Ascendis Pharma A/S Stock Up 2.7 %

NASDAQ:ASND opened at $140.30 on Friday. The company has a market cap of $8.51 billion, a P/E ratio of -17.36 and a beta of 0.67. Ascendis Pharma A/S has a twelve month low of $111.09 and a twelve month high of $161.00. The business has a 50 day moving average price of $129.27 and a two-hundred day moving average price of $132.75.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Groupama Asset Managment acquired a new position in shares of Ascendis Pharma A/S in the third quarter valued at approximately $60,000. Janus Henderson Group PLC boosted its stake in Ascendis Pharma A/S by 6.8% in the 3rd quarter. Janus Henderson Group PLC now owns 4,186,694 shares of the biotechnology company’s stock valued at $625,075,000 after purchasing an additional 267,881 shares during the period. Avoro Capital Advisors LLC grew its holdings in Ascendis Pharma A/S by 5.8% in the 2nd quarter. Avoro Capital Advisors LLC now owns 4,196,661 shares of the biotechnology company’s stock valued at $572,341,000 after buying an additional 229,995 shares in the last quarter. Westfield Capital Management Co. LP increased its position in Ascendis Pharma A/S by 3.4% during the 3rd quarter. Westfield Capital Management Co. LP now owns 5,133,766 shares of the biotechnology company’s stock worth $766,523,000 after buying an additional 170,942 shares during the period. Finally, Massachusetts Financial Services Co. MA lifted its holdings in shares of Ascendis Pharma A/S by 9.1% during the third quarter. Massachusetts Financial Services Co. MA now owns 1,866,986 shares of the biotechnology company’s stock worth $278,760,000 after buying an additional 155,971 shares in the last quarter.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.